-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Avalon GloboCare (ALBT) Vs. Its Competitors Critical Contrast
Avalon GloboCare (ALBT) Vs. Its Competitors Critical Contrast
Avalon GloboCare (NASDAQ:ALBT – Get Rating) is one of 60 publicly-traded companies in the "Management consulting services" industry, but how does it contrast to its rivals? We will compare Avalon GloboCare to similar companies based on the strength of its profitability, risk, earnings, valuation, dividends, analyst recommendations and institutional ownership.
Profitability
This table compares Avalon GloboCare and its rivals' net margins, return on equity and return on assets.
Get Avalon GloboCare alerts:Net Margins | Return on Equity | Return on Assets | |
Avalon GloboCare | -955.48% | -460.58% | -97.43% |
Avalon GloboCare Competitors | -56.87% | -79.82% | -7.02% |
Volatility and Risk
Avalon GloboCare has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Avalon GloboCare's rivals have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.
Valuation & Earnings
This table compares Avalon GloboCare and its rivals gross revenue, earnings per share (EPS) and valuation.Gross Revenue | Net Income | Price/Earnings Ratio | |
Avalon GloboCare | $1.39 million | -$9.09 million | -2.59 |
Avalon GloboCare Competitors | $1.54 billion | $108.11 million | 13.68 |
Avalon GloboCare's rivals have higher revenue and earnings than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
0.9% of Avalon GloboCare shares are held by institutional investors. Comparatively, 41.3% of shares of all "Management consulting services" companies are held by institutional investors. 64.0% of Avalon GloboCare shares are held by company insiders. Comparatively, 29.2% of shares of all "Management consulting services" companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Avalon GloboCare and its rivals, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Avalon GloboCare | 0 | 0 | 0 | 0 | N/A |
Avalon GloboCare Competitors | 54 | 447 | 965 | 15 | 2.64 |
As a group, "Management consulting services" companies have a potential upside of 45.39%. Given Avalon GloboCare's rivals higher possible upside, analysts clearly believe Avalon GloboCare has less favorable growth aspects than its rivals.
Summary
Avalon GloboCare rivals beat Avalon GloboCare on 9 of the 10 factors compared.
Avalon GloboCare Company Profile
(Get Rating)
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. It operates through the following segments: Real Property Operating, Medical Related Consulting Services, and Development Services & Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.
Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.
阿瓦隆GloboCare(纳斯达克:ALBT-GET Rating)是管理咨询服务行业60家上市公司之一,但与竞争对手相比有何不同?我们将根据Avalon GloboCare的盈利能力、风险、收益、估值、股息、分析师建议和机构所有权等方面的实力,将其与类似公司进行比较。
盈利能力
此表比较了Avalon GloboCare及其竞争对手的净利润率、股本回报率和资产回报率。
到达阿瓦隆GloboCare警报:净利润率 | 股本回报率 | 资产回报率 | |
阿瓦隆GloboCare | -955.48% | -460.58% | -97.43% |
Avalon GloboCare竞争对手 | -56.87% | -79.82% | -7.02% |
波动性和风险
Avalon GloboCare的贝塔系数为0.69,这意味着其股价的波动性比标准普尔500指数低31%。相比之下,Avalon GloboCare的竞争对手的贝塔系数为1.76,这意味着它们的平均股价波动性比标准普尔500指数高76%。
估值与收益
此表比较了Avalon GloboCare及其竞争对手的毛收入、每股收益(EPS)和估值。总收入 | 净收入 | 市盈率 | |
阿瓦隆GloboCare | 139万美元 | -909万元 | -2.59 |
Avalon GloboCare竞争对手 | 15.4亿美元 | 1.0811亿美元 | 13.68 |
Avalon GloboCare的竞争对手比Avalon GloboCare的收入和收益更高。Avalon GloboCare的市盈率低于竞争对手,这表明它目前比行业内的其他公司更实惠。
机构与内部人持股
Avalon GloboCare 0.9%的股份由机构投资者持有。相比之下,所有管理咨询服务公司41.3%的股份由机构投资者持有。Avalon GloboCare 64.0%的股份由公司内部人士持有。相比之下,所有管理咨询服务公司29.2%的股份由公司内部人持有。强大的机构持股表明,捐赠基金、大型基金经理和对冲基金相信,从长期来看,一只股票的表现将好于大盘。
分析师评级
这是由MarketBeat.com提供的Avalon GloboCare及其竞争对手最近的评级和目标价细目。
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
阿瓦隆GloboCare | 0 | 0 | 0 | 0 | 不适用 |
Avalon GloboCare竞争对手 | 54 | 四四七 | 965 | 15个 | 2.64 |
作为一个整体,“管理咨询服务”公司有45.39%的潜在上行空间。鉴于Avalon GloboCare的竞争对手更有可能上行,分析师显然认为Avalon GloboCare的增长方面不如竞争对手有利。
摘要
Avalon GloboCare的竞争对手在比较的10个因素中有9个击败了Avalon GloboCare。
Avalon GloboCare公司简介
(获取评级)
Avalon GloboCare Corp.是一家控股公司,从事生物技术的开发和医疗保健服务的提供。它通过以下部门运作:房地产运营、医疗相关咨询服务、开发服务和已开发产品的销售。它通过Avalon Cell和Avalon Rehab平台提供再生医学、基于细胞的免疫疗法、Exosome技术和康复医学。该公司成立于2014年7月28日,总部位于新泽西州弗里霍尔德。
接受Avalon GloboCare Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Avalon GloboCare和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧